Importance of JAMA Research & Future Zantac Lawsuits
Written By: Peter Soares
The Journal of the American Medical Association (JAMA) is a peer-reviewed medical journal. It publishes original research focusing on biomedicine, and is published by the American Medical Association 48 times per year. JAMA has published critical medical articles with respect to drug labeling, and is currently researching the potential connection between ranitidine based drugs (such as Zantac) and the development of cancer. This research is expected to have a tremendous impact on the ongoing litigation against the manufacturers of ranitidine based drugs, such as Zantac.
In 2014, JAMA Published the study Drug Labeling and Exposure in Neonates (Neonates are newborn children). The study examined “a cohort of drug studies between 1997 and 2010.” The study examined 446,335 hospitalized infants, 399 drugs, and 1,525,739 drug exposures in 28 postnatal days. One of the most intriguing takeaways from the study is that “ranitidine was used most often.” This is especially alarming due to the fact that many law firms are currently filing lawsuits against the manufacturers of ranitidine based drugs, alleging that consumption of ranitidine drugs during pregnancy may result in the development of testicular cancer in newborns.
Current Litigation Against Manufacturers of Ranitidine Based Drugs, & Zantac
Recently, the popular antacid drug Zantac has come under scrutiny after Valisure, an independent pharmaceutical research company, discovered the drug may cause high levels of the carcinegion NDMA (N-Nitrosodimethylamine). Many are worried that regular consumption of Zantac over long periods of time may have caused the development of specific cancers, such as leukemia. Lior Braunstein, who is co-leading research efforts by Memorial Sloan Kettering Cancer Center, is currently looking into whether NDMA levels in generic and brand-name Zantac may be linked to an increased risk of cancer. As of the writing of this article, researchers at JAMA are currently investigating the potential connection between the ranitidine based drug, Zantac, and the development of cancer.
Lawsuits are currently being filed against Zantac manufacturers alleging the NDMA compound in Zantac may have been transferred to babies in the womb, resulting in testicular cancer of newborn boys. Until recently, the link between Zantac and cancer causing NDMA was not disclosed by Zantac manufacturers to the general public, and many pregnant mothers may have been unknowingly exposing their babies to the carcinegion NDMA.
Do You have a Zantac Cancer Lawsuit?
The attorneys at Rheingold Giuffra Ruffo & Plotkin LLP have decades worth of experience successfully litigating dangerous drug cases against large pharmaceutical corporations. We are currently speaking with individuals who may have developed cancer as a result of prolonged Zantac use. Please reach out to our law firm if you or a loved one developed cancer while taking Zantac. Our attorneys will schedule an appointment to speak with you about your specific case and needs. You can reach our New York office location by calling (888) 260-0473.